(VIANEWS) – Halozyme Therapeutics (HALO), Matador Resources Company (MTDR), Owens Corning (OC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Halozyme Therapeutics (HALO)
33.5% sales growth and 153.16% return on equity
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Halozyme Therapeutics has a trailing twelve months EPS of $2.58.
PE Ratio
Halozyme Therapeutics has a trailing twelve months price to earnings ratio of 24.75. Meaning, the purchaser of the share is investing $24.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 153.16%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 33.3% and 56.1%, respectively.
2. Matador Resources Company (MTDR)
28.6% sales growth and 23.96% return on equity
Matador Resources Company, an independent energy company, engages in the exploration, development, production, and acquisition of oil and natural gas resources in the United States. It operates through two segments, Exploration and Production; and Midstream. The company primarily holds interests in the Wolfcamp and Bone Spring plays in the Delaware Basin in Southeast New Mexico and West Texas. It also operates the Eagle Ford shale play in South Texas; and the Haynesville shale and Cotton Valley plays in Northwest Louisiana. In addition, the company conducts midstream operations in support of its exploration, development, and production operations. Further, it provides natural gas processing and oil transportation services; and oil, natural gas, and produced water gathering services, as well as produced water disposal services to third parties. The company was formerly known as Matador Holdco, Inc. and changed its name to Matador Resources Company in August 2011. Matador Resources Company was founded in 2003 and is headquartered in Dallas, Texas.
Earnings Per Share
As for profitability, Matador Resources Company has a trailing twelve months EPS of $7.77.
PE Ratio
Matador Resources Company has a trailing twelve months price to earnings ratio of 7.48. Meaning, the purchaser of the share is investing $7.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.96%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Aug 15, 2024, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 1.38%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 4.8% and 21.1%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 31.7%, now sitting on 3.02B for the twelve trailing months.
Volume
Today’s last reported volume for Matador Resources Company is 1062060 which is 40.49% below its average volume of 1784900.
3. Owens Corning (OC)
22.4% sales growth and 19.86% return on equity
Owens Corning engages in manufacture and sale of insulation, roofing, and fiberglass composite materials in the United States, Canada, Europe, the Asia Pacific, Latin America, and internationally. It operates in three segments: Composites, Insulation, and Roofing. The Composites segment manufactures, fabricates, and sells glass reinforcements in the form of fiber; and glass fiber products in the form of fabrics, non-wovens, and other specialized products. Its products are used in building structures, roofing shingles, tubs and showers, pools, decking, flooring, pipes and tanks, poles, electrical equipment, and wind-energy turbine blades. This segment sells its products directly to parts molders, fabricators, and shingle manufacturers. The Insulation segment manufactures and sells thermal and acoustical batts, loosefill insulation, spray foam insulation, foam sheathing and accessories under the Owens Corning PINK, and FIBERGLAS brands; and glass fiber pipe insulation, energy efficient flexible duct media, bonded and granulated mineral wool insulation, cellular glass insulation, and foam insulation under the FOAMULAR, FOAMGLAS, and Paroc brand names used in construction applications. This segment sells its products primarily to the insulation installers, home centers, lumberyards, retailers, and distributors. The Roofing segment manufactures and sells laminate and strip asphalt roofing shingles, oxidized asphalt materials, and roofing components used in residential and commercial construction, and specialty applications, as well as synthetic packaging materials. This segment sells its products through distributors, home centers, lumberyards, retailers, and contractors, as well as to roofing contractors for built-up roofing asphalt systems; and manufacturers in automotive, chemical, rubber, and construction industries. The company was incorporated in 1938 and is headquartered in Toledo, Ohio.
Earnings Per Share
As for profitability, Owens Corning has a trailing twelve months EPS of $11.83.
PE Ratio
Owens Corning has a trailing twelve months price to earnings ratio of 14.14. Meaning, the purchaser of the share is investing $14.14 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.86%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jul 15, 2024, the estimated forward annual dividend rate is 2.4 and the estimated forward annual dividend yield is 1.4%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.8%, now sitting on 9.87B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 2.7% and a negative 1.9%, respectively.
Previous days news about Owens Corning(OC)
- Owens corning stock declines in the past 3 months: things to note. According to Zacks on Tuesday, 3 September, "Lackluster Volume in Q3: For the third quarter, Owens Corning expects Roofing revenues to be flat to down slightly year over year. "
- Owens corning (oc) increases despite market slip: here's what you need to know. According to Zacks on Wednesday, 4 September, "In the latest trading session, Owens Corning (OC Quick QuoteOC – Free Report) closed at $159.98, marking a +0.23% move from the previous day. ", "In the context of valuation, Owens Corning is at present trading with a Forward P/E ratio of 10.37. "
4. First Financial Bankshares (FFIN)
21.2% sales growth and 13.96% return on equity
First Financial Bankshares, Inc., through its subsidiaries, provides commercial banking products and services in Texas. The company offers checking, savings and time deposits; automated teller machines, drive-in, and night deposit services; safe deposit facilities, remote deposit capture, internet banking, mobile banking, payroll cards, funds transfer, and performing other customary commercial banking services; securities brokerage services; and trust and wealth management services, including wealth management, estates administration, oil and gas management, testamentary trusts, revocable and irrevocable trusts, and agency accounts. It also provides commercial and industrial, municipal, agricultural, construction and development, farm, residential, and consumer auto and non-auto, as well as non-owner occupied and owner occupied commercial real estate loans. In addition, the company offers advisory and specialized services related to asset management, investing, purchasing, advertising, public relations, and technology services. First Financial Bankshares, Inc. was founded in 1890 and is headquartered in Abilene, Texas.
Earnings Per Share
As for profitability, First Financial Bankshares has a trailing twelve months EPS of $1.41.
PE Ratio
First Financial Bankshares has a trailing twelve months price to earnings ratio of 25.94. Meaning, the purchaser of the share is investing $25.94 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.96%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 11.4% and 21.9%, respectively.
Moving Average
First Financial Bankshares’s value is above its 50-day moving average of $33.84 and way above its 200-day moving average of $30.95.
5. Neurocrine Biosciences (NBIX)
20.8% sales growth and 15.55% return on equity
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Neurocrine Biosciences has a trailing twelve months EPS of $3.32.
PE Ratio
Neurocrine Biosciences has a trailing twelve months price to earnings ratio of 38.27. Meaning, the purchaser of the share is investing $38.27 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.55%.
Moving Average
Neurocrine Biosciences’s value is way below its 50-day moving average of $143.86 and under its 200-day moving average of $135.72.
Volume
Today’s last reported volume for Neurocrine Biosciences is 1236880 which is 43.96% above its average volume of 859176.
Previous days news about Neurocrine Biosciences(NBIX)
- According to Zacks on Wednesday, 4 September, "In December 2019, Xenon entered into a collaboration agreement with Neurocrine Biosciences (NBIX Quick QuoteNBIX – Free Report) granting the latter an exclusive license to XEN901, now known as NBI-921352, which is a selective Nav1.6 sodium channel inhibitor. "
